New hope for rare sarcoma: targeted drug trial opens

NCT ID NCT06942442

Recruiting now Disease control Sponsor: Sarcoma Alliance for Research through Collaboration Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called tebentafusp in people with a rare and advanced type of cancer called clear cell sarcoma. Only patients with a specific genetic marker (HLA-A*02:01) can join. The goal is to see if the drug can stop the cancer from growing for at least 24 weeks. About 47 participants will take part in this phase 2 trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HLA-A*0201 POSITIVE CELLS PRESENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell sarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL SARCOMA (CCS) HLA-A*0201 POSITIVE CELLS PRESENT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Southern California - Norris Cancer Center
RECRUITING

Los Angeles, California, 90033, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••